现成的 CAR-T 细胞可能为自身免疫性疾病带来范式转变。
Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases.
机构信息
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA 19104, USA; Cardiovascular Institute, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, PA 19104, USA.
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA 19104, USA.
出版信息
Cell. 2024 Sep 5;187(18):4826-4828. doi: 10.1016/j.cell.2024.07.056.
Early reports suggest that chimeric antigen receptor (CAR)-T therapy has remarkable potential for treating autoimmune disease. Current approaches rely on autologous CAR-T cells, creating a bottleneck to the broad deployment of this therapy. In this issue of Cell, Wang et al. report the first use of allogeneic CAR-T cells in three patients with systemic autoimmune disease.
早期报告表明，嵌合抗原受体 (CAR)-T 疗法在治疗自身免疫性疾病方面具有显著的潜力。目前的方法依赖于自体 CAR-T 细胞，这给这种疗法的广泛应用带来了瓶颈。在本期《细胞》杂志上，Wang 等人报道了首例在 3 名系统性自身免疫性疾病患者中使用同种异体 CAR-T 细胞的情况。
Zotero 插件